Division Director, Gynecologic Oncology
Medical Education: The Johns Hopkins University School of Medicine, MD, 1977
Residency: The Johns Hopkins Hospital, Gynecology and Obstetrics, 1981
Fellowship: M.D. Anderson Cancer Center, Gynecologic Oncology, 1983
American Board of Obstetrics and Gynecology, Obstetrics and Gynecology, 1984
American Board of Obstetrics and Gynecology, Gynecologic Oncology, 1985
American College of Obstetricians and Gynecologists
Society of Gynecologic Oncologists
Felix Rutlege Society
American Society of Clinical Oncology
International Society of Gynecologic Oncology
European Society of Medical Oncology
American College of Surgeons
The Johns Hopkins Medical and Surgical Society
National Faculty Award, American College of Obstetrics and Gynecology, 2001
Outstanding Teacher, Department of Obstetrics and Gynecology, Banner Good Samaritan Medical Center, 2005-2006
Emory University Hospital Midtown
Directions and Map
Emory University Hospital Midtown
Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, Vaccarello L, Homesley HD, McMeekin S, Burkholder TL, Wang Y, Zhao L, Orlando M, Obasaju CK, Gill JF, Tai DF. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol 123(3):479-85, 2011.
Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non- Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. Oncol Pract 6(3):133-40, 2010.
Chambers SK, Clouser MC, Baker AF, Roe DJ, Cui H, Brewer MA, Hatch KD, Gordon MS, Janicek MF, Isaacs JD, Gordon AN, Nagle RB, Wright HM, Cohen JL, Alberts DS. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 16(21):5320-8, 2010.
Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or sup optimally debulked stage III epithelial ovarian cancer. J Clin Oncol 26:2674-2682, 2008.
Mutch DG, Orlando M Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR, Marciniak, Naumann RW, Secord AA. Randomized phase III trial of gemcitabene compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007.
Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12:72-8, 2007
Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Alberts DS, Weems G, Cullen, McGuire WP. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 101:55-61, 2006
Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Erwin DH, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a Phase II multicenter study. Int J Gynecol Oncol 15:1-8, 2005.
Im SS, Gordon AN, Buttin BM, Leath III CA, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML. Validation of Referral Guidelines for Women with Pelvic Masses. Obstet Gynecol 105:35-41, 2005.
Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB. SCOTROC 1: Phase III Randomized Trial of Docetaxel-Carboplatin versus Paclitaxel- Carboplatin as First-line Chemotherapy for Ovarian Carcinoma. J NCI 96:1692-91, 2004.
Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Rivkin S, Schultes BC, Whiteside TL, Nicodemus CF. Randomized Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients with Ovarian Cancer. J Clin Oncol 22:3507-16, 2004.
Gordon AN, Tonda M, Sun S, Rackoff W. Long-term Survival Advantage for Women Treated With Pegylated Liposomal Doxorubicin Compared With Topotecan in a Phase 3 Randomized Study of Recurrent and Refractory Epithelial Ovarian Cancer. Gynecol Oncol 95:1-8, 2004.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-9, 2004.
Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH, Bailey CL, Savage J, Young JA. Phase II Study of Sequential Doublets: Topotecan and Carboplatin, Followed by Paclitaxel and Carboplatin, in Patients With Newly Diagnosed Advanced Ovarian Cancer. Gynecol Oncol 94:533-9, 2004.
Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, Nicodemus CF. CA125- and Tumor-Specific T-Cell Responses Correlate with Prolonged Survival in Oregovomab- treated Recurrent Ovarian Cancer Patients. Gynecol Oncol 94:340-351, 2004.
Chan SY, Gordon AN, Coleman RE, Hall JB, Berger MS, Sherman ML, Eten CB, Finkler NJ. A phase II study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian cancinoma. Cancer Immunology Immunotherapy 52:243-8,2003.
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, Odile D, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L and Zou W. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:5:562-567, 2003.
Smith DH, Adams JR, Johnston SRD, Gordon A, Drummond MF, Bennett CL. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Annals Oncology 13: 1590-1597, 2002.
Gordon AN, Hancock KC, Matthews CM, Messing M, Stringer CA, Doherty MG, Teneriello M. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer. Gynecol Oncol 85:129-135, 2002.
Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P, Capron F, Emilie D, Curiel TJ. Stomal derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339-1346, 2001.
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin versus Topotecan. J Clin Oncol 19:3312-3322, 2001.
Gore M, Huinink WtB, Carmichael J, Gordon A, Davidson N, Coleman R, Spanczynski M, Heron JF, Bolis G, Malmstrom H, Malfetano J, Scarabelli C, Vennin P, Ross G, Fields SZ. Clinical evidence for topotecan – paclitaxel noncross-resistance in ovarian cancer. J Clin Oncol 19:1893-1900,2001.
Gordon AN, Granai CO, Rose P, Hainsworth, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II Study of Stealth® Liposomal Doxorubicin (Doxil®) in Platinum and Paclitaxel Refractory Epithelial Ovarian Cancer. J Clin Oncol 18:3093-3100,2000.
Gordon AN, Hancock KC, Matthews CM, Stringer CA, Boston J, Neumanitis J. A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. Am J Clin Oncol 22:601-605,1999.
Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the Treatment of Advanced Epithelial Ovarian Cancer: An Open-Label Phase II Study in Patients Treated After Prior Chemotherapy Containing Cisplatin or Carboplatin and Paclitaxel. J Clin Oncol 16:3345-3352, 1998.
Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC and Heron JF. Topotecan versus Paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997.
Gordon AN, Stringer CA, Matthews CM, Willis DL and Nemunaitis J. Phase I dose escalation of Paclitaxel in patients with advanced ovarian cancer receiving Cisplatin: Rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965-1973, 1997.
Fleischer AC, McKee MS, Gordon AN, Page DL, Kepple DM, Worrell JA, Jones III HW, Burnett LS, James Jr AE: Transvaginal Sonography of postmenopausal ovaries with pathologic correlation. J Ultrasound Med 9:637-644, 1990
Stringer CA, Gershenson DM, Burke TS, Edwards CL, Gordon AN, Wharton JT: Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high- risk endometrial cancer: A preliminary analysis. Gynecol Oncol 38:305-308, 1990
Gordon AN, Fleischer AC, Reed GW: Depth of myometrial invasion in endometrial cancer: Pre-operative assessment by transvaginal sonography. Gynecol Oncol 39:321-327, 1990
Levitan Z, Kaplan A, Gordon AN: Survival following malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer. South Med J 83:241-242, 1990
Gordon AN, Montag T: Sarcoma botryoides of the cervix: Excision followed by adjuvant chemotherapy for preservation of reproductive function. Gynecol Oncol 36:119-124, 1990
Gordon AN, Bornstein J, Kaufman RH, Estrada RG, Adams E, Adler-Storthz K: Human papillomavirus associated with adenocarcinoma and adenosquamous carcinoma of the cervix: Analysis by in situ hybridization. Gynecol Oncol 35:345-348, 1989
Gordon AN, Martens M, LaPread Y, Faro S: Response of lower genital tract flora to external pelvic irradiation. Gynecol Oncol 35:233-235, 1989.
Fleischer AC, Gordon AN, Entman SS: Transvaginal sonography of palpable adnexal masses: Does it add specificity? Ultrasound Med Biol 15: 529-533, 1989
Gordon AN, Jensen R, Jones HW: Squamous carcinoma of the cervix complicating pregnancy; recurrence in the episiotomy following vaginal delivery. Obstet Gynecol 73:850- 852, 1989
Gordon AN, Fleischer AC, Dudley BS, Drolshagan LF, Kalemaris GC, Partain CL, Jones HW, Burnett LS: Preoperative assessment of myometrial invasion of endometrial adenocarcinoma by sonography (US) and magnetic resonance imaging (MRI). Gynecol Oncol 34:175-179, 1989
Gordon AN, Gershenson DM, Copeland LJ, Stringer CA, Morris M, Wharton JT: High-risk metastatic gestational trophoblastic disease: Further stratification into two clinical entities. Gynecol Oncol 34:54-56, 1989
Levitan Z, Gordon AN, Kaplan AL, Kaufman RH: Primary malignant melanoma of the vagina: Report of four cases and review of the literature. Gynecol Oncol 33:85-90, 1989.
VanSickle M, Gordon AN, Lynch GR: Chemotherapeutic response consolidated with radiation in adenocarcinoma of the cervix with para-aortic nodal metastasis. Am J Gynecol Health 5:12-15, 1989
Gordon AN, Lynch GR: Multi-agent chemotherapy in combination with fractionated radiation therapy for advanced carcinoma of the cervix: Acute toxicity. Eur J Gynaec Oncol 9:351-354, 1988
Kirshon B, Young R, Gordon AN: Conservative management of abdominal gunshot in pregnancy. Am J Perinatol 5:232-233, 1988
Reeves KO, Young RL, Gordon AN, Thomas Jr SJ, Redwine WA, Edward GR: Sigmoidovaginal fistula secondary to diverticular disease. J Reprod Med 33:313-316, 1988
Pruett KM, Gordon AN, Estrada R, Lynch GR: Small cell carcinoma of the ovary: An Aggressive epithelial cancer occurring in young patients. Gynecol Oncol 29: 365-369, 1988
Dieste MC, Lynch GR, Gordon AN, Estrada R, Lane M: Malignant fibrous histiocytoma of the broad ligament: A case report and literature review. Gynecol Oncol 28:225-229, 1987
Kaufman RH, Bornstein J, Gordon A, Adam E, Kaplan AL, Adler-Storthz K: Detection of human papillomavirus DNA in advanced epithelial ovarian carcinoma. Gynecol Oncol 27:340-350, 1987
Gordon AN, Kavanagh JJ, Gershenson DM, Saul PB, Copeland LJ, Stringer, CA: Cisplatinum, vinblastine and bleomycin combination therapy in resistant gestational trophoblastic disease. Cancer 58:1407-1410, 1986
Gordon AN, Johnson JWC: Value of umbilical blood acid-base studies in fetal assessment. J Reprod Med 30:329-336, 1985
Gordon AN, Gershenson DM, Copeland LJ, Saul PB, Kavanagh JJ, Edwards CL: High-risk metastatic gestational trophoblastic disease. Obstet Gynecol 65:550-556, 1985
Gordon AN, Kavanagh JJ, Wharton JT, Rutledge FN, Obbens EA, Bodey GP: Successful treatment of leptomeningeal relapse of epithelial ovarian cancer. Gynecol Oncol 18:119- 124, 1984
Gordon AN, Lipton DJ, Woodruff JD: Dysgerminoma: Review of 158 cases from the Emil Novak Tumor Registry. Obstet Gynecol 58:497-504, 1981
Gordon A, Rosenshein N, Parmley T, Bhagavan B: Benign cystic teratomas in post- menopausal women. Am J Obstet Gynecol 138:1120-1123, 1980
Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rode PJ. Role of Pegelated Liposomal Doxorubicin in Ovarian Cancer. Gynecol Oncol 96:10-8, 2005.
Markman M, Gordon AN, McGuire WP, Muggia FM. Liposomal Anthracycline Treatment for Ovarian Cancer. Semin Oncol 31:91-105, 2004
Huinink W, Carmichael J, Armstrong D, Gordon A and Malfetano J. Efficacy and safety of Topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol 24 (suppl 5):55- 19-55-25, 1997.
Gordon AN: Current concepts in the treatment of invasive vulvar carcinoma. Clin Obstet Gynecol 34:587-598, 1991
Fleischer AC, Gordon AN, Entman SS, Kepple DM: Transvaginal sonography (TVS) of the endometrium: Current and potential clinical applications. Crit Reviews Diag Imaging 30:85- 110, 1990
Kaufman RH, Gordon AN: Squamous cell carcinoma of the vulva: Part II. Brit J Sex Med 13:55-58, 1986
Kaufman RH, Gordon AN: Squamous cell carcinoma of the vulva: Part I. Brit J Sex Med 13:24 27, 1986
Gordon AN: Vulvar Cancer. In Clinical Gynecology (Eds. Bieber EJ, Sanfilippo JS, Horowitz IR) Philadelphia, Pennsylvania, Churchill Livingstone, 2nd Edition, in press
Gordon AN: Vulvar Cancer. In Clinical Gynecology (Eds. Bieber EJ, Sanfilippo JS, Horowitz IR) Philadelphia, Pennsylvania, Churchill Livingstone, 2006
Gordon AN: Vulvar neoplasms. In Textbook of Gynecology (Ed. Copeland LJ) Philadelphia, Pennsylvania, W.B. Saunders Company, 2nd Edition, 2000
Gordon AN: Vulvar neoplasms. In Textbook of Gynecology (Ed. Copeland LJ) Philadelphia, Pennsylvania, W.B. Saunders Company, 1992
Gordon AN: Neoplasms of the vulva. In Conn's Current Therapy (Ed. Rakel RE) Philadelphia, Pennsylvania, W.B. Saunders Company, 1990
Fleischer AC, Gordon AN, Page DL, James AE: The present and potential roles of transvaginal sonography in the early detection of ovarian carcinoma: Theoretic and practical considerations. In Principles and Practice of Ultrasonography in Obstetrics and Gynecology (Eds. Fleischer A, Romero R, Jeanty P, Manning F, James AE) Norwald, Connecticut, Appleton and Lang Publishers, 1989
Fleischer AC, Gordon AN, Entman SS, Kepple DM: Transvaginal sonography (TVS) of the endometrium: Current and potential clinical applications. In Principles and Practice of Ultrasonography in Obstetrics and Gynecology (Eds. Fleischer A, Romero R, Jeanty P, Manning F, James AE) Norwald, Connecticut, Appleton and Lang Publishers, 1989
Fleischer AC, Gordon AN: Sonography of trophoblastic diseases. In Principles and Practice of Ultrasonography in Obstetrics and Gynecology (Eds. Fleischer A, Romero R, Jeanty P, Manning F, James AE) Norwald, Connecticut, Appleton and Lang Publishers, 1989
Gordon AN: Gestational trophoblastic disease. In Principles and Practice of Clinical Gynecology (Eds. Kase NG, Weingold AB, Gershenson DM) New York, John Wiley and Sons, Inc. 1989
Gordon AN, Kaufman RH: Sarcoma and lymphoma. In Female Genital Cancer (Eds. Gusburg SB, Shingleton HM Deppe G) New York, Churchill Livingstone, Inc., 1988